Table 2 Participants’ diabetes and binge eating outcomes (n = 21)
Characteristic | Mean (range) | N (%) | |
|---|---|---|---|
Diabetes diagnosis | |||
Type 2 diabetes | 10 (48) | ||
Current hemoglobin A1c (%) | 8.4 (6.4–14.0) | ||
Diabetes duration (years) | 12 (5–18) | ||
Insulin use (% yes)* | 3 (15) | ||
Non-insulin T2DM medication use (% yes)* | 9 (45) | ||
Metformin | 8 | ||
Sulfonylurea | 2 | ||
Thiazolidinedione | 1 | ||
DPP-4 inhibitor | 1 | ||
GLP-1 receptor agonist | 1 | ||
SGLT2 inhibitor | 1 | ||
Prediabetes | 11 (52) | ||
Years since prediabetes diagnosis | 5.7 (1–19) | ||
Number progressing to T2DM diagnosis | 1 (9) | ||
Age/Life stage of binge onset (self-reported) | |||
Childhood | 11 (52) | ||
Adolescence | 4 (19) | ||
Young adulthood | 4 (19) | ||
Middle adulthood | 2 (10) | ||
Frequency of binge eating episodes (at time of interview) | |||
< 1x/month | 5 (24) | ||
1-2x/month | 2 (10) | ||
1x/week | 4 (19) | ||
2-3x/week | 3 (14) | ||
4-6x/week | 2 (10) | ||
1x/day | 3 (14) | ||
> 1x/day | 2 (10) | ||
EDE-Q scores** | |||
Global Score | 2.6 (0.6–5.3) | ||
Restraint | 1.5 (0–3.6) | ||
Eating concern | 2.5 (0–6) | ||
Shape concern | 3.1 (0.3–6) | ||
Weight concern | 3.5 (0.5–6) | ||